Your browser is no longer supported. Please, upgrade your browser.
Collegium Pharmaceutical, Inc.
Index- P/E47.96 EPS (ttm)0.50 Insider Own1.70% Shs Outstand34.54M Perf Week7.36%
Market Cap766.72M Forward P/E15.93 EPS next Y1.50 Insider Trans-8.85% Shs Float32.19M Perf Month30.20%
Income17.60M PEG87.19 EPS next Q0.31 Inst Own- Short Float12.09% Perf Quarter26.82%
Sales307.90M P/S2.49 EPS this Y42.80% Inst Trans0.84% Short Ratio13.01 Perf Half Y41.60%
Book/sh5.00 P/B4.79 EPS next Y73.44% ROA3.20% Target Price28.43 Perf Year13.04%
Cash/sh5.16 P/C4.64 EPS next 5Y0.55% ROE12.60% 52W Range13.00 - 25.59 Perf YTD19.47%
Dividend- P/FCF9.35 EPS past 5Y5.70% ROI-24.00% 52W High-6.49% Beta1.08
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin52.20% 52W Low84.08% ATR1.16
Employees255 Current Ratio1.10 Sales Q/Q8.60% Oper. Margin12.60% RSI (14)67.62 Volatility5.85% 5.27%
OptionableYes Debt/Eq1.55 EPS Q/Q276.40% Profit Margin5.70% Rel Volume0.94 Prev Close23.62
ShortableYes LT Debt/Eq1.27 EarningsNov 05 AMC Payout0.00% Avg Volume299.04K Price23.93
Recom2.10 SMA2013.79% SMA5020.33% SMA20024.02% Volume280,839 Change1.31%
Jan-11-21Reiterated H.C. Wainwright Buy $29 → $33
Jul-14-20Initiated BWS Financial Sell $8
May-27-20Initiated Guggenheim Neutral
Feb-19-20Resumed Jefferies Buy $43
Oct-30-19Reiterated Needham Buy $33 → $25
May-03-19Resumed H.C. Wainwright Buy $23
Apr-12-19Resumed Janney Buy $29
Mar-20-19Initiated SunTrust Hold $22
Jan-16-19Reiterated Needham Buy $35 → $33
Mar-08-18Reiterated H.C. Wainwright Buy $21 → $33
Feb-07-18Reiterated Needham Buy $28 → $35
Dec-05-17Reiterated Needham Buy $25 → $28
Sep-11-17Initiated H.C. Wainwright Buy $21
May-11-17Reiterated Needham Buy $28 → $25
Sep-13-16Initiated Gabelli & Co Buy $25
Jun-01-15Initiated Piper Jaffray Overweight $26
Jun-01-15Initiated Needham Buy $28
Jun-01-15Initiated Jefferies Buy $20
Jan-06-21 04:01PM  
Dec-16-20 05:48PM  
Nov-07-20 08:36AM  
Nov-06-20 10:31PM  
Nov-05-20 05:45PM  
Oct-29-20 12:35PM  
Oct-26-20 08:00AM  
Oct-25-20 07:05AM  
Oct-22-20 04:01PM  
Oct-12-20 01:25PM  
Oct-04-20 06:51AM  
Sep-30-20 08:00AM  
Sep-25-20 08:00AM  
Sep-14-20 08:00AM  
Sep-09-20 04:05PM  
Aug-07-20 11:39AM  
Aug-05-20 07:15PM  
Aug-04-20 12:04PM  
Aug-03-20 12:59PM  
Jul-29-20 12:33PM  
Jul-21-20 05:00PM  
Jul-07-20 11:40AM  
Jun-19-20 11:40AM  
Jun-17-20 05:09PM  
Jun-03-20 11:40AM  
May-27-20 08:44AM  
May-18-20 11:40AM  
May-13-20 11:06AM  
May-08-20 12:31PM  
May-07-20 04:01PM  
Apr-30-20 12:34PM  
Apr-23-20 04:01PM  
Apr-07-20 04:01PM  
Apr-06-20 09:30AM  
Apr-01-20 08:50AM  
Mar-26-20 11:40AM  
Mar-24-20 05:03AM  
Mar-20-20 07:44AM  
Mar-10-20 11:40AM  
Feb-27-20 04:01PM  
Feb-26-20 01:05PM  
Feb-20-20 12:31PM  
Feb-13-20 04:01PM  
Feb-10-20 07:15PM  
Feb-08-20 07:04AM  
Feb-07-20 07:32AM  
Feb-06-20 04:01PM  
Jan-31-20 05:00PM  
Jan-21-20 08:41AM  
Jan-14-20 11:50AM  
Jan-09-20 08:39AM  
Jan-08-20 08:12AM  
Jan-07-20 04:05PM  
Dec-13-19 11:32AM  
Dec-10-19 05:43PM  
Dec-06-19 02:39PM  
Nov-26-19 08:01AM  
Nov-08-19 08:14AM  
Nov-06-19 06:25PM  
Oct-30-19 10:34AM  
Oct-23-19 08:00AM  
Oct-19-19 10:02AM  
Sep-26-19 04:08PM  
Sep-25-19 08:00AM  
Sep-23-19 06:00AM  
Sep-03-19 04:01PM  
Aug-29-19 04:01PM  
Aug-08-19 11:24PM  
Aug-07-19 06:35PM  
Jul-31-19 10:36AM  
Jul-24-19 04:01PM  
Jul-23-19 12:19PM  
Jun-28-19 05:03PM  
Jun-19-19 10:41AM  
May-29-19 08:00AM  
May-09-19 10:03PM  
May-08-19 05:45PM  
May-06-19 11:54AM  
May-05-19 09:19AM  
May-01-19 10:33AM  
Apr-30-19 04:01PM  
Apr-24-19 04:01PM  
Apr-02-19 08:00AM  
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kuhlmann Shirley R.EVP and General CounselJan 20Sale24.456,081148,680103,582Jan 21 04:29 PM
Dreyer ScottEVP & Chief Commercial OfficerJan 15Sale22.891,32230,26144,395Jan 20 04:15 PM
Fleming Alison BChief Technology OfficerJan 07Option Exercise5.7316,04291,921127,461Jan 11 05:06 PM
Fleming Alison BChief Technology OfficerJan 07Sale22.0016,042352,924111,419Jan 11 05:06 PM
Fleming Alison BChief Technology OfficerDec 03Sale19.245,967114,805111,419Dec 07 04:03 PM
Fleming Alison BChief Technology OfficerNov 18Option Exercise5.7316,00091,680117,386Nov 20 04:28 PM
Kuhlmann Shirley R.EVP and General CounselOct 15Sale20.827,060146,98957,531Oct 16 04:07 PM
Heffernan Michael ThomasDirectorAug 11Sale19.1313,071250,04854,122Aug 12 04:05 PM
Dreyer ScottEVP & Chief Commercial OfficerJul 13Sale17.011,42924,30746,418Jul 14 04:06 PM
Ciaffoni JosephPresident and CEOJun 02Sale20.485,861120,058192,798Jun 02 06:58 PM
Ciaffoni JosephPresident and CEOJun 01Option Exercise8.2264,820532,820269,335Jun 02 06:58 PM
Ciaffoni JosephPresident and CEOJun 01Sale21.5370,6761,521,709198,659Jun 02 06:58 PM
Dreyer ScottEVP & Chief Commercial OfficerMay 18Option Exercise15.908,000127,20056,441May 20 04:18 PM
Dreyer ScottEVP & Chief Commercial OfficerMay 18Sale24.008,000192,00048,441May 20 04:18 PM
Fleming Alison BChief Technology OfficerMay 13Sale21.677,989173,147102,901May 15 04:16 PM
Heffernan Michael ThomasDirectorMay 13Sale21.6319,254416,42181,796May 15 04:17 PM
Dreyer ScottEVP & Chief Commercial OfficerMay 13Sale22.614,434100,25348,441May 15 04:15 PM